December 18, 2025 · Form 4 insider transaction
Chambers Michael Andrew sold an undisclosed number of shares of Sarepta Therapeutics, Inc., a transaction worth N/A. The trade was recorded as disposition to the issuer and disclosed on an SEC Form 4, filed 1 day after the transaction.
On December 10, 2025, the Reporting Person and the Company entered into an exchange agreement related to the exchange by the Reporting Person of $20,000,000 in aggregate principal amount of the Company's 1.25% Convertible Senior Notes due 2027 (the "2027 Notes") for a combination of (i) $20,000,000 in aggregate principal amount of the Company's 4.875% Convertible Senior Notes due 2030 (the "2030 Notes") and (ii) $2,170,006.66 in cash in a private exchange with the Company. The exchange closed on December 18, 2025.; The 2027 Notes are convertible at the election of the holder at any time prior to the close of business on the business day immediately preceding March 15, 2027, provided that certain convertibility conditions are met. On or after March 15, 2027 until the close of business on the second scheduled trading day immediately preceding the maturity date (September 15, 2027), holders may convert their notes at any time, regardless of the foregoing circumstances. Any conversion of the 2027 Notes may be settled in shares of Common Stock, cash or a combination of cash and shares of Common Stock at the Company's election.